The SPOTLIGHT study evaluated the diagnostic performance and safety of prostate-specific membrane antigen–targeting radiopharmaceutical, 18F-flotufolastat, in a large multi-institutional population of men from across the United States and Europe who had recurrent prostate cancer.8 This evidence concerns the gene FOLH1 and Familial prostate cancer.